

# Huiping Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3990914/publications.pdf>

Version: 2024-02-01

61  
papers

1,048  
citations

623734

14  
h-index

477307

29  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1740  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	1.6	226
2	Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 149.	2.6	77
3	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. <i>Nature Communications</i> , 2018, 9, 1614.	12.8	76
4	Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 17-33.	2.5	74
5	Transferrin Functionization Elevates Transcytosis of Nanogranules across Epithelium by Triggering Polarity-Associated Transport Flow and Positive Cellular Feedback Loop. <i>ACS Nano</i> , 2019, 13, 5058-5076.	14.6	50
6	Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 18423-18428.	8.0	47
7	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , 2017, 18, 371-383.	10.7	43
8	Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1080.	1.6	43
9	Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29
10	Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381982870.	1.9	26
11	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1837-1846.	1.4	26
12	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	2.5	25
13	Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles. <i>Small Methods</i> , 2018, 2, 1800122.	8.6	20
14	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 370-382.	2.2	18
15	Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 330-338.	2.2	17
16	Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm. <i>Theranostics</i> , 2017, 7, 4710-4721.	10.0	14
17	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 315-326.	2.2	14
18	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 242.	1.7	14

#	ARTICLE	IF	CITATIONS
19	<p></p>Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer</p>. Cancer Management and Research, 2020, Volume 12, 3547-3560.	1.9	13
20	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 149-162.	2.2	12
21	Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. Frontiers in Oncology, 2020, 10, 587671.	2.8	12
22	Identification of recurrent <sc>BRCA</sc> 1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Medicine, 2017, 6, 547-554.	2.8	11
23	Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. Journal of Cancer, 2020, 11, 6612-6622.	2.5	11
24	An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 586-600.	2.2	10
25	Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 396-402.	1.1	9
26	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.. Journal of Clinical Oncology, 2020, 38, 3638-3638.	1.6	9
27	Differential impact of tumor-infiltrating immune cells on basal and luminal cells: implications for tumor invasion and metastasis. Anticancer Research, 2014, 34, 6363-80.	1.1	9
28	Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. Cancer Chemotherapy and Pharmacology, 2021, 88, 131-141.	2.3	8
29	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Journal of Translational Medicine, 2022, 20, 211.	4.4	8
30	First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters, 2015, 9, 987-993.	1.8	7
31	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Targeted Oncology, 2021, 16, 701-741.	3.6	7
32	<p></p>Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab</p>. OncoTargets and Therapy, 2020, Volume 13, 4385-4395.	2.0	6
33	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. Targeted Oncology, 2021, 16, 591-599.	3.6	6
34	Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). Cancer Medicine, 2021, 10, 6089-6098.	2.8	6
35	Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 243-255.	2.2	6
36	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncology Letters, 2020, 20, 1-1.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Liquid Biospy: Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles (Small Methods) Tj ETQq1.4 0.784814 rgBT (C	1.4	0
38	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. Cancer Management and Research, 2021, Volume 13, 3303-3316.	1.9	5
39	Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 608781.	2.8	5
40	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
41	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 403-418.	1.6	4
42	Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study. Advances in Therapy, 2019, 36, 131-146.	2.9	4
43	The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anti-Cancer Drugs, 2022, 33, e635-e643.	1.4	4
44	Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 189, 725-736.	2.5	4
45	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 1031-1031.	1.6	4
46	Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 550-7.	2.2	3
47	Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 650-663.	0.5	3
48	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast Cancer Research and Treatment, 2021, 190, 213-226.	2.5	2
49	Efficacy and safety of PEG-rhG-CSF in primary and secondary prevention of chemotherapy-induced neutropenia.. Journal of Clinical Oncology, 2019, 37, e19051-e19051.	1.6	1
50	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncology Letters, 2020, 20, 378.	1.8	1
51	Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial. Cancer Research, 2022, 82, P2-13-31-P2-13-31.	0.9	1
52	Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer. Frontiers in Oncology, 2022, 12, 745796.	2.8	1
53	A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 5539-5539.	1.6	1
54	Response to Sung, Rosenberg, and Yang. Journal of the National Cancer Institute, 2020, 112, 547-548.	6.3	0

#	ARTICLE	IF	CITATIONS
55	Prognostic factors for patients with metastatic breast cancer: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 1644-1655.	1.0	0
56	Incidence of neutropenia in breast cancer patients with administration of mecapegfilgrastim.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24070-e24070.	1.6	0
57	Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1003-1003.	1.6	0
58	Methylomes variation to predict exemestane resistance in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24029-e24029.	1.6	0
59	A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2526-2526.	1.6	0
60	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 535-535.	1.6	0
61	Phase II randomized trial of different nab-paclitaxel dose schedule in patients with HER-2 negative recurrent/metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13050-e13050.	1.6	0